

RENCA cells

Mouse RENCA cells are derived from a spontaneous renal cortical adenocarcinoma in BALB/C.

Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of BALB/C mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing RENCA tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.




Figure 1: Tumour growth curve of the RENCA cells as subcutaneous tumours
Mean \pm SEM (n=4; take rate 100%)

Drug Responses

Anti-PD1 12.5 mg/kg \rightarrow Response

Anti-PDL1 12.5 mg/kg \rightarrow Response

Immunophenotyping data of the lymphoid and myeloid lineage are available upon request.

Antineo has developed models of secondary resistance to anti-PD1/PD-L1 (ID RENCA anti-PD1R and RENCA anti-PDL1R). These models have been developed *in vivo* without genetic modifications.